Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.35 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2103838 | 0.84 | ACVR1 (0.43) | SLC5A2 | |
| SCHEMBL2103863 | 0.76 | PYGL (0.46) | SLC5A2PYGL | |
| SCHEMBL260163 | 0.76 | SLC5A2 (0.37) | SLC5A2PYGL | |
| SCHEMBL3902748 | 0.76 | SLC5A2 (0.40) | SLC5A2PYGL | |
| SCHEMBL260215 | 0.76 | SLC5A2 (0.39) | SLC5A2PYGL | |
| SCHEMBL2104719 | 0.74 | SLC5A2 (0.39) | SLC5A2 | |
| SCHEMBL2102022 | 0.73 | SLC5A2 (0.37) | SLC5A2PYGL | |
| SCHEMBL2102763 | 0.72 | MAPT (0.35) | PYGL | |
| SCHEMBL2102605 | 0.72 | PYGL (0.33) | SLC5A2PYGL | |
| SCHEMBL2101894 | 0.72 | SLC5A2 (0.36) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | claimed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | claimed |
| US-20130078218-A1 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | disclosed |
| EP-2537520-A1 | Hepatics C therapies | Biocryst Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | disclosed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1863500-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060234963-A1 | Hepatitis C therapies | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-10-19 | — | — | US | disclosed |
| WO-2006104945-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | OGA 3830/4885SLC5A2 1587/4885SLC29A1 89/4885 |
| US-20130078218-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | OGA 2567/4885SLC5A2 2049/4885SLC29A1 1443/4885 |
| US-20060234963-A1 | Hepatitis C therapies | HAVCR2, FABP1, LIPC | OGA 2567/4885SLC5A2 2049/4885SLC29A1 1443/4885 |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | DPYD, TYMP, TYMS | OGA 3830/4885SLC5A2 1587/4885SLC29A1 89/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | OGA 3830/4885SLC5A2 1587/4885SLC29A1 89/4885 |
| US-20100143300-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | OGA 2567/4885SLC5A2 2049/4885SLC29A1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.